TransEnterix Inc. announced a third-quarter loss on Monday that slightly beat analysts’ estimates, and the firm also announced the installation of its Senhance system at another location, according to a filing with the Securities and Exchange Commission.

TransEnterix reported a third-quarter loss of 11 cents per share, compared to a loss of 16 cents per share in the same period last year. Analysts were forecasting a loss of 12 cents.

The company reported revenue of $1.5 million for the quarter, largely representing the sale of one Senhance system and related services, the press release said. TransEnterix also said it has cash and cash equivalents on hand of approximately $52.9 million, which will fund operations into the fourth quarter of 2017.

Morrisville-based TransEnterix is currently focused on the commercialization of its Senhance system, which is a robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with technology such as haptic feedback and eye sensing camera control.

“We are pleased with our recent progress, which included the first sale of a Senhance system and the continued development of our commercial pipeline,” said Todd M. Pope, president and CEO, in a statement. “We remain enthusiastic about the potential of Senhance, and will continue to invest in global commercial expansion, including partnering with additional influential institutions to establish clinical reference sites.”

TransEnterix stock, traded under the ticker symbol “TRXC,” will open at $1.63 on Monday and was seen trading up as much as 9 percent in early hours. The stock has seen a 52-week low of $1.03 and a 52-week high of $6.10.

The company is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery. The company is also working on the development of the SurgiBot System, a single-port, robotically enhanced laparoscopic surgical platform.

The complete third-quarter earnings report and press release can be found here.